Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes–focus on venlafaxine and O-desmethylvenlafaxine

被引：0
|
作者：
Mani Kandasamy
P. Srinivas
Kala Subramaniam
Sandhya Ravi
James John
Radha Shekar
Nuggehally Srinivas
Saral Thangam
机构：
[1] Lotus Labs,Biometrics
[2] Lotus Labs Pvt. Ltd.,Bioanalytical
[3] Lotus Labs Pvt. Ltd.,Clinical
[4] Suramas Biopharm,Drug Development
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
CYP2D6; Venlafaxine; O-desmethyvenlafaxine; Pharmacokinetics; Bioavailability;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：879 / 887
页数：8
相关论文
共 50 条
  • [1] Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes-focus on venlafaxine and O-desmethylvenlafaxine
    Kandasamy, Mani
    Srinivas, P.
    Subramaniam, Kala
    Ravi, Sandhya
    John, James
    Shekar, Radha
    Srinivas, Nuggehally
    Thangam, Saral
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (09) : 879 - 887
  • [2] Association between CYP2D6 genotype and venlafaxine and O-desmethylvenlafaxine concentrations and efficacy: Results from two French studies
    Konecki, C.
    Colle, R.
    Chappell, K.
    Tayeb, A. E. K. Ait
    Becquemont, L.
    Corruble, E.
    Verstuyft, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2022, 36 : 41 - 42
  • [3] The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort
    Kringen, Marianne K.
    Braten, Line S.
    Haslemo, Tore
    Molden, Espen
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2020, 40 (02) : 137 - 144
  • [4] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    M. Hermann
    M. Hendset
    K. Fosaas
    M. Hjerpset
    H. Refsum
    European Journal of Clinical Pharmacology, 2008, 64 : 483 - 487
  • [5] Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele
    Hermann, M.
    Hendset, M.
    Fosaas, K.
    Hjerpset, M.
    Refsum, H.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (05) : 483 - 487
  • [6] INCREASED SUM CONCENTRATION OF VENLAFAXINE AND O-DESMETHYLVENLAFAXINE AND RISK OF SIDE EFFECTS IN COMBINED CYP2D6/CYP2C19 POOR METABOLIZERS
    Kringen, M. K.
    Haslemo, T.
    Molden, E.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 6 - 6
  • [7] Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype
    Mannheimer, Buster
    Haslemo, Tore
    Lindh, Jonatan D.
    Eliasson, Erik
    Molden, Espen
    THERAPEUTIC DRUG MONITORING, 2016, 38 (01) : 127 - 134
  • [8] Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
    Haslemo, Tore
    Eliasson, Erik
    Jukic, Marin M.
    Ingelman-Sundberg, Magnus
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (01) : 194 - 201
  • [9] Correlation between CYP2D6 geno-and phenotypes with clinical outcomes under antidepressant treatment with venlafaxine
    Shams, M
    Arneth, B
    Lackner, K
    Hiemke, C
    Haertter, S
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S339 - S340
  • [10] Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
    L Karlsson
    A-L Zackrisson
    M Josefsson
    B Carlsson
    H Green
    F C Kugelberg
    The Pharmacogenomics Journal, 2015, 15 : 165 - 171
12345